| scholarly article | Q13442814 |
| P50 | author | Sara Campagna | Q58327367 |
| Riccardo Sperlinga | Q85910271 | ||
| P2093 | author name string | S Paoletti | |
| A Berruti | |||
| G V Scagliotti | |||
| R Rosato | |||
| M Tucci | |||
| A Saini | |||
| P L Giuliano | |||
| P Laciura | |||
| I Ginosa | |||
| P2860 | cites work | Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 |
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study | Q33873528 | ||
| Guidelines for the process of cross-cultural adaptation of self-report measures | Q34109955 | ||
| Impact and management of breakthrough pain in cancer | Q34975545 | ||
| The Alberta Breakthrough Pain Assessment Tool for cancer patients: a validation study using a delphi process and patient think-aloud interviews | Q37051857 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| Assessment and classification of cancer breakthrough pain: a systematic literature review | Q37710813 | ||
| Which variables are associated with pain intensity and treatment response in advanced cancer patients?--Implications for a future classification system for cancer pain | Q37786092 | ||
| Pharmacotherapy for breakthrough cancer pain | Q37974707 | ||
| Considerations in selecting rapid-onset opioids for the management of breakthrough pain | Q38090468 | ||
| Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature | Q38116663 | ||
| Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies | Q39229667 | ||
| A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain | Q39280743 | ||
| Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain | Q39297474 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Optimization of opioid therapy for preventing incident pain associated with bone metastases | Q39374560 | ||
| Characterization of breakthrough pain by hospice patients and their caregivers | Q39444429 | ||
| Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients | Q39449130 | ||
| Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 | ||
| Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study | Q43568437 | ||
| Guidelines for the management of breakthrough pain in patients with cancer | Q43827105 | ||
| Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain | Q44105804 | ||
| The prevalence of episodic pain in cancer: a survey of hospice patients on admission | Q44221667 | ||
| Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 | ||
| Episodic (Breakthrough) Pain Prevalence in a Population of Cancer Pain Patients. Comparison of Clinical Diagnoses With the QUDEI—Italian Questionnaire for Intense Episodic Pain | Q57758048 | ||
| Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice | Q74317837 | ||
| A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain | Q79301299 | ||
| Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients | Q87754420 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 881-888 | |
| P577 | publication date | 2014-11-05 | |
| P1433 | published in | European Journal of Pain | Q4548992 |
| P1476 | title | Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain | |
| P478 | volume | 19 |
| Q36832225 | A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting |
| Q36807866 | Canadian recommendations for the management of breakthrough cancer pain |
| Q92910003 | Characteristics of Breakthrough Pain and Its Impact on Quality of Life in Terminally Ill Cancer Patients |
| Q39170820 | Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer |
| Q98892344 | Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines on Pharmacological Management of Cancer Pain (Part II) |
| Q39144886 | Multidimensional Treatment of Cancer Pain |
| Q91496796 | Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study |
| Q61813535 | The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients |
Search more.